<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623231</url>
  </required_header>
  <id_info>
    <org_study_id>0600-15</org_study_id>
    <nct_id>NCT02623231</nct_id>
  </id_info>
  <brief_title>The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients</brief_title>
  <acronym>Cipralex&amp;GBM</acronym>
  <official_title>The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Testing the effect of providing an antidepressant and anxiety-type escitalopram for patients&#xD;
      with glioblastoma on patient's quality of life including the effect of treatment on mood and&#xD;
      cognition during treatment.Two subgroups will fill questionnaires :&#xD;
&#xD;
        -  Questionnaire mini mental state exam (mmse) which is the maximum score of 30. A score of&#xD;
           below 24 indicates a flaw in the level of dementia&#xD;
&#xD;
        -  Questionnaire depression / mood PHQ9P(Pa t i e n t H e a l t h Qu e s t i o n n a i r e&#xD;
           - 9)&#xD;
&#xD;
        -  The M. D. Anderson Symptom Inventory (MDASI)&#xD;
&#xD;
        -  Evaluation of the hospital situation awareness (clinical assessment and questionnaire)&#xD;
&#xD;
        -  Cognitive assessment which will be carried out by the Department neuropsychological and&#xD;
           include:&#xD;
&#xD;
             -  Executive function (Stroop)&#xD;
&#xD;
             -  Abstract Reasoning (similarities)&#xD;
&#xD;
             -  -Auditory and Spatial Attention (Digit span, Spatial span) visual memory and&#xD;
                remembering Literature&#xD;
&#xD;
             -  Memory function - visual and auditory (ROCF, RAVLT)&#xD;
&#xD;
             -  Language function: Naming and verbal fluency&#xD;
&#xD;
             -  Mindstreems Neurotrax&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is planned as prospective randomized, controlled, double-blind study.&#xD;
&#xD;
      Patients will undergo resection or biopsy of glioblastoma (newly diagnosed glioblastoma),&#xD;
      will randomization ratio of 1: 1 by the pharmacist (by age,Karnofsky score, extent of tumor&#xD;
      resection), for two research groups:&#xD;
&#xD;
      Group number 1 will include 50 patients, who will receive Escitalopram or Placebo at a dose&#xD;
      of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months. . The dose&#xD;
      study is fixed and is not aimed at symptomatic treatment of anti-depressant (such as major&#xD;
      depression).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in patients mood and cognitive function according to the neuropsychological assessment that includes patient health questionnaire (PHQ9)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>GBM</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group number 2 will include 50 patients, who will receive Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months</description>
    <arm_group_label>escitalopram</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Cipralex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months</description>
    <arm_group_label>escitalopram</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:* men and women&#xD;
&#xD;
          -  Aged 18-80&#xD;
&#xD;
          -  who signed an informed consent form&#xD;
&#xD;
          -  patients that underwent biopsy or resection of brain glioblastoma.&#xD;
&#xD;
          -  KPSâ‰¥70&#xD;
&#xD;
          -  Patients that are stable in terms of seizures who take only one antiepileptic drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who suffered from depression within five years,&#xD;
&#xD;
          -  Patients treated with antidepressants&#xD;
&#xD;
          -  Are not able to answer the questionnaires because of an inability to communicate&#xD;
&#xD;
          -  Patients treated with inhibitors (MAOI) such as: nialamide , isocarboxazid ,&#xD;
             iproniazid, phenerzine, tranylcypromine&#xD;
&#xD;
          -  Patients who suffer from epilepsy.&#xD;
&#xD;
          -  Patients who suffer from Parkinson's&#xD;
&#xD;
          -  Patients who suffer from cardiac dysfunction or heart attack recently.&#xD;
&#xD;
          -  Patients with eye problems in expanding pupils - can result in the development of&#xD;
             glaucoma and closed angle.&#xD;
&#xD;
          -  Severe renal dysfunction. (creatinine clearance &lt;30 mL / min). , Creatinine less than&#xD;
             1.5 times the upper limit of normal or end-stage renal disease&#xD;
&#xD;
          -  Hepatic insufficiency -bilirubin General&gt; 1.5 times the upper limit of normal, Hepatic&#xD;
             Enzymes less than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  a score of less than 24 test The mini-mental state examination (MMSE)&#xD;
&#xD;
          -  allergy to any component of the drug- Talc, croscarmellose sodium, Microcrystalline&#xD;
             Cellulose silicified, Magnesium stearate, Hypromellose, Macrogol 400, Titanium Dioxide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Grossman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>tasmc,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Grossman, MD</last_name>
    <phone>972-3-6972731</phone>
    <email>rachelg@tlvmc.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmit Ben Harosh, RN</last_name>
    <phone>6974397</phone>
    <email>Carmitbh@tlvmc.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>michal roll</investigator_full_name>
    <investigator_title>Director of R &amp; D department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

